Formerly Known as Evgen Pharma Plc3 May 2024 20:13
TheraCryf PLC formally known as Eve is a clinical stage therapeutics company that is developing a new generation of innovative therapeutics in oncology and behavioral brain disorders.
Their strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma1.
The company was formerly known as Evgen Pharma plc, and it acquired Chronos Therapeutics in April 20241.
TheraCryf’s clinical asset is SFX-01, a patented sulforaphane-based medicine1. They are also working on neuropsychiatry assets that use novel chemistry to address highly relevant targets in brain health1.
TheraCryf is focusing on developing commercially successful products, targeting certain cancers and behavioural brain disorders1. They have several ongoing projects, including:
SFX-01 and glioblastoma: Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times1.
NCE Ox-1 in Addiction and Anxiety Disorders: TheraCryf has a candidate stage antagonist molecule targeting the orexin 1 receptor with high specificity1.
NCE Atypical DAT inhibitor in Fatigue and Narcolepsy: The Company has a candidate stage atypical inhibitor of the brain dopamine transporter mechanism1.